Tag: healing

Glass House Brands Announces the Filing of Shelf Prospectus and At-The-Market Distribution Program

LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that it has filed a short form base shelf prospectus (the “Shelf Prospectus”) dated June 10, 2026 with the securities regulatory authorities in all provinces and territories of Canada. The Shelf Prospectus replaces the Company’s prior short form base shelf prospectus, which was set to expire on June 17, 2026.

NY Business Leaders Come Out in Force to Support Global Hope & Healing Via the Human-Animal Bond

NEW YORK, June 10, 2026 /PRNewswire/ -- Executives from New York's major investment banks and law firms packed the Edison Ballroom this past Wednesday...

PTC Unveils a Wave of Product Innovations to Give Manufacturers New AI Capabilities and Connected Tools Across the Intelligent Product Lifecycle

Introduces PTC Orbit and PTC Jetstream, a new AI platform, 12 AI agents, 10 new integrations, and 100+ enhancements across CAD, PLM, ALM, and...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

GENESIS AND GENESIS INSPIRATION FOUNDATION PROMOTE STEAM LEARNING IN CHICAGO

Child Creativity Lab STEAM workshop with Boys & Girls Clubs of Chicago cultivates design thinking skillsGenesis Inspiration Foundation awards $25,000 grant to Creative Netwerk...

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).

SONIFI showcases how hotels can set a new standard with their guest technology and managed services at HITEC 2026

LOS ANGELES, June 9, 2026 /PRNewswire/ -- Hospitality's largest global guest technology managed services provider, SONIFI, is unveiling its latest innovations at the annual...

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...

voco™ Scenia Bay Nha Trang Celebrates Global Wellness Day, International Yoga Day and an Invitation to The Show

NHA TRANG, Vietnam, June 9, 2026 /PRNewswire/ -- This June, voco™ Scenia Bay Nha Trang by IHG invites guests to discover a fresh approach...

Strong Indonesian Demand Reinforces Malaysia Healthcare’s Growth at Malaysia Fair 2026

JAKARTA, Indonesia, June 9, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC), together with Tourism Malaysia, recorded strong visitor engagement at Malaysia Fair Jakarta 2026,...

InventHelp Inventor Develops New Itch Relief Product (CNH-6076)

PITTSBURGH, June 8, 2026 /PRNewswire/ -- "I thought there should be a convenient way to apply heat to an itch to activate transient receptor...

Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will be accessible by Zoom webinar (the “Webinar”). The in-person meeting will be held on Thursday, June 18, 2026 at Perkins Place Office Building, located at 525 Portland Street, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

MILESEEY Tools und magicplan geben strategische Partnerschaft bekannt und stellen gemeinsames Co-Branding S50R-Lasermessset vor

Finance firms face surging AI risks as conduct incidents average USD 14 million